Published in Women's Health Weekly, January 13th, 2005
This is the first time Wyeth has applied simultaneously for global approval of a new product. This registration package included the submission of a new drug application (NDA) with the U.S. Food and Drug Administration (FDA), as well as a marketing authorization application (MAA) with the European Medicines Agency and additional filings with authorities in Canada, Australia, and Switzerland.
Wyeth is seeking market approval for Tygacil as a single agent therapy to treat...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.